Mirae Asset Management said it listed the TIGER Technology Transfer Bio Active ETF on the Korea Exchange on March 17 after selecting and investing in domestic KOSDAQ bio companies.

The product is an active ETF that uses the KRX Technology Transfer Bio Index announced by the Korea Exchange as its benchmark. It mainly invests in listed domestic KOSDAQ bio stocks. It focuses on the technology transfer, or license-out, theme, which is cited as a key growth driver of South Korea's bio industry.

The initial portfolio was built with biotech companies such as LikaChem Bio, OliX and ABL Bio as major holdings, accounting for about 86.8 percent. It also included traditional drugmakers such as Samchundang Pharm, Hanmi Pharmaceutical, ST Pharm and Celltrion to pursue stability and growth at the same time.

Won-taek Jung (정원택), head of Equity Investment Division 3 at Mirae Asset Management, said, "As the government stresses fostering biotech as a key industry for revitalising KOSDAQ, the technological competitiveness of domestic bio companies is also rising rapidly." He added, "We expect this product will be a means to invest efficiently in the growth of KOSDAQ biotech."